Our Services
Neurology & Oncology
Brain Tumours
Precision-guided stereotactic radiosurgery (SRS) and fractionated radiotherapy for primary brain tumours, metastases, and benign lesions — delivering therapeutic doses with sub-millimetre accuracy while protecting eloquent cortex.
Single-fraction or hypofractionated treatment for brain metastases, meningiomas, and acoustic neuromas.
Conformal dose sculpting around critical structures — optic nerves, brainstem, hippocampus.
Neurocognitive preservation in patients receiving prophylactic or therapeutic whole-brain irradiation.
Advanced Radiation Therapy
Head & Neck Cancers
Advanced image-guided radiotherapy for oral, oropharyngeal, laryngeal, hypopharyngeal, and thyroid cancers — maximizing locoregional control while preserving swallowing, voice, and quality of life through precise dose sculpting.
Dose painting with parotid gland and spinal cord sparing to reduce xerostomia and neurological toxicity.
Weekly or 3-weekly cisplatin with definitive or adjuvant RT for advanced-stage disease.
Careful cumulative dose assessment with BED calculations for recurrent or second primary tumours.
Nutrition counselling, mucosal care, and swallowing therapy coordinated throughout treatment.
SBRT · Stereotactic Body RT
Lung & Liver Tumours
Stereotactic Body Radiotherapy (SBRT) delivers ablative-dose radiation in a small number of fractions with extreme precision — ideal for early-stage lung cancer, oligometastatic disease, and unresectable hepatocellular carcinoma.
Motion-encompassing ITV delineation to track tumour throughout the breathing cycle — reducing margins and protecting healthy lung.
Deep inspiration breath-hold technique for liver SBRT, minimising hepatic dome movement during beam delivery.
Daily imaging with couch corrections for sub-millimetre positional accuracy before every fraction.
Esophageal . Rectal
Esophageal & Rectal Cancers
Specialized multimodality radiotherapy for gastrointestinal cancers — combining neoadjuvant chemoradiation, definitive CRT, and organ-preservation strategies with meticulous planning to protect bowel, bladder, and spinal cord.
Weekly carboplatin + paclitaxel with 41.4 Gy / 23 fractions prior to esophagectomy — improving R0 resection rates and pCR.
50–50.4 Gy with concurrent cisplatin/5-FU for inoperable or patient-choice organ preservation, particularly in SCC.
25 Gy / 5 fx (Swedish protocol) or 45–50.4 Gy CRT (German CAO/ARO) — watch-and-wait strategy for clinical complete responders.
RAPIDO and PRODIGE-23 informed consolidation chemotherapy + CRT for high-risk rectal cancer to maximise organ preservation.
